Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8016782 | 0.86 | ALDH1A1 (0.57) | TSHRCYP3A4RECQLRAB9AMEN1 | |
| SCHEMBL4830911 | 0.83 | MAPT (0.49) | RAB9AMEN1LMNAMAPTKMT2A | |
| SCHEMBL23797950 | 0.83 | MAPT (0.46) | TSHRCYP3A4RECQLRAB9AMEN1 | |
| SCHEMBL13577700 | 0.82 | HDAC6 (0.68) | TSHRCYP3A4RAB9AMEN1LMNA | |
| SCHEMBL13936274 | 0.81 | GAA (0.49) | TSHRCYP3A4RECQLRAB9AMEN1 | |
| SCHEMBL7651532 | 0.81 | GAA (0.60) | TSHRCYP3A4RAB9AMEN1LMNA | |
| SCHEMBL11138178 | 0.81 | CA12 (0.48) | TSHRMEN1LMNAMAPTKMT2A | |
| SCHEMBL9824176 | 0.80 | TSHR (0.47) | TSHRCYP3A4RECQLRAB9AMEN1 | |
| SCHEMBL23293735 | 0.80 | TGM2 (0.47) | TSHRCYP3A4RECQLRAB9AMEN1 | |
| SCHEMBL30050717 | 0.79 | MAPT (0.55) | RAB9AMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | TSHR 2245/4885CYP3A4 259/4885RECQL 3886/4885 |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | KEAP1, NFE2L2, BACH1 | TSHR 4053/4885CYP3A4 744/4885RECQL 3397/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | TSHR 716/4885CYP3A4 638/4885RECQL 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.